Leadership Team
About
The Leadership Team at Akero Therapeutics is responsible for setting the strategic direction of the company and overseeing its clinical development efforts in the pursuit of innovative treatments for non-alcoholic steatohepatitis (NASH). Comprising key executives such as the President & CEO, Chief Scientific Officer, and COO, this team collaborates to ensure efficient operations, drive fundraising, and advance the progress of their lead product candidate, efruxifermin (EFX), through clinical trials while maintaining high standards of quality and regulatory compliance.